Novel Therapeutic Approaches to Asthma in Clinical Medicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy in Clinical Medicine".

Deadline for manuscript submissions: closed (25 August 2025) | Viewed by 1949

Special Issue Editor


E-Mail
Guest Editor
Department of Respiratory Medicine, Copenhagen University Hospital—Amager and Hvidovre, 2650 Hvidovre, Denmark
Interests: lung diseases; asthma; respiration; allergy

Special Issue Information

Dear Colleagues,

Asthma is a chronic respiratory condition affecting millions globally. Despite advancements in treatment, it remains a significant cause of morbidity, leading to an ongoing search for more effective therapies.

Traditional treatments, such as inhaled corticosteroids and bronchodilators, have been the cornerstone of asthma management for decades. However, their limitations in addressing severe and treatment-resistant cases have led to the exploration of novel therapeutic approaches.

This Special Issue aims to explore cutting-edge treatments that go beyond traditional therapies, including biologics, personalized medicine, and innovative drug delivery systems. The goal is to enhance the effectiveness of asthma care and improve patient outcomes.

We are particularly interested in emerging treatments such as monoclonal antibodies targeting specific immune pathways, gene therapy, and microbiome-related interventions, all of which have shown promising results in early clinical trials.

We are soliciting original research articles, reviews, and other papers that focus on novel therapies for asthma. Papers that discuss new treatment modalities, biomarkers for therapy selection, and patient-centered approaches are particularly welcome.

Dr. Howraman Meteran
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma management
  • novel asthma therapies
  • biologic treatments for asthma
  • personalized medicine in asthma
  • monoclonal antibodies
  • severe asthma
  • precision medicine
  • immune-modulating therapies
  • gene therapy in asthma
  • innovative drug delivery systems
  • microbiome and asthma
  • inflammation control in asthma
  • asthma biomarkers
  • airway remodeling
  • corticosteroid alternatives

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 2270 KB  
Review
Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review
by Philip F. Lavere, Kaitlin M. Phillips, Nicola A. Hanania and Muhammad Adrish
J. Pers. Med. 2025, 15(8), 370; https://doi.org/10.3390/jpm15080370 - 13 Aug 2025
Viewed by 1730
Abstract
Chronic airway inflammation with variable airflow obstruction is clinical asthma, and it arises from distinct molecular and pathological mechanisms called endotypes. Biomarkers allow for precise endotype characterization and have been used in clinical trials to design, monitor, and evaluate outcomes for asthma biologic [...] Read more.
Chronic airway inflammation with variable airflow obstruction is clinical asthma, and it arises from distinct molecular and pathological mechanisms called endotypes. Biomarkers allow for precise endotype characterization and have been used in clinical trials to design, monitor, and evaluate outcomes for asthma biologic therapies. This review will highlight the central and evolving role of biomarkers for past, present, and future asthma, with a focus on regulatory-approved biologic therapies and emerging biomarkers. Established biomarkers, including serum immunoglobulin E (IgE), blood eosinophils, the fraction of exhaled nitric oxide (FeNO), and serum periostin, helped elucidate the complex pathophysiology of the eosinophilic type 2 (T2) asthma endotype. Emerging biomarkers, or older biomarkers with emerging utility, include sputum inflammatory cells (eosinophils, neutrophils, interleukins), thymus and activation-regulated chemokine (TARC), plasma eotaxin-3, eosinophil peroxidase (EPX), Clara/club cell secretory protein (CC16), and quantitative computerized tomography (QCT) imaging biomarkers (evaluating mucus plugging, air trapping, airway wall thickness, small airway remolding) and are increasingly used in clinical trials as secondary endpoints in evaluating efficacy, as well as in the clinical setting at specialized centers. The rapid advances in asthma research, due in part to biomarkers and biologic therapies, may soon standardize an end goal: symptom-free asthma remission without exacerbations. Full article
(This article belongs to the Special Issue Novel Therapeutic Approaches to Asthma in Clinical Medicine)
Show Figures

Figure 1

Back to TopTop